BACARDI
30.3.2022 12:32:07 CEST | Business Wire | Press release
Bacardi, the largest privately held spirits company in the world, is raising the bar for cocktails-at-home with the launch of TAILS COCKTAILS.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005116/en/
This is the first time this new range of premium batched cocktails from TAILS will be available for consumers to enjoy at home. The brand was originally created for the hospitality industry, offering a hassle-free solution for serving premium quality cocktails easily, quickly and consistently.
“Over the last two years, cocktail awareness has boomed as people served up daiquiris, espresso martini cocktails and mojitos to make staying-in feel extra special,” said Evert-Jan Bos, General Manager of TAILS. “Now, as the on-trade reopens, consumers are enjoying the experience of being back in the bar and they’re ordering cocktails more than ever before.”
To tap into this thriving cocktail culture, TAILS is bringing a taste of the bar home with new-look packaging and new recipes. Made using the Bacardi portfolio of premium brands blended with top quality ingredients, the pre-batched cocktail range is perfectly positioned for the rise in entertaining at home, and an ever-growing demand for hyper-convenience. People can now enjoy the experience of shaking up a bar quality cocktail in just 30 seconds, with no planning required.
Evert-Jan adds: “This is a game-changer for the home bar. TAILS COCKTAILS offer both incredible taste and convenience, making it easier than ever for people to enjoy the same flavor and complexity of a cocktail made from scratch, without any effort or expertise. No shopping for ingredients, no measuring, no recipes - just add ice, shake and pour – how easy is that?”
There are five TAILS COCKTAILS - the ‘Rum Daiquirí’ made with BACARDÍ® rum; the ‘Whisky Sour’ with DEWAR’S® Blended Scotch whisky; the ‘Gin Gimlet’ with BOMBAY SAPPHIRE® gin; and the ‘Espresso Martini Cocktail’ and ‘Passion Fruit Martini Cocktail’, both made with 42BELOW® vodka.
Francis Debeuckelaere, Regional President, Western Europe, Australia & New Zealand, comments: “Of course you can never replace the experience of enjoying a favorite cocktail in a local bar, however we’re going one step further to offer more and more fantastic choices for consumers. With TAILS we’re delivering new experiences for the home, putting cocktails on the menu whatever the occasion. We are pioneering a whole new ‘ready-to-shake’ category.”
A QR code on every 50cl bottle links to a 30 second ‘how to’ video which explains the three simple serving steps, along with garnish suggestions, for each cocktail: 1, add ice and 125ml of the TAILS cocktail to a shaker; 2, experience that ‘bartender feeling’ by shaking until ice cold; and 3, pour into a glass.
TAILS will be available from April in supermarkets, specialist liquor stores and online across the UK & Ireland, Netherlands, Belgium, Germany, Austria, and Australia, supported by a digital-first marketing campaign focused on building awareness and driving trial of the new range.
For more information on TAILS COCKTAILS, visit www.tailscocktails.com .
Always drink responsibly.
About TAILS®
TAILS COCKTAILS is an exclusive range of premium pre-batched cocktails that bring the experience of the bar to consumers’ homes, with all the flavor and complexity of hand-made cocktails, but none of the effort. Established in 2010, TAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS COCKTAIL begins with the highest quality, premium spirits – BACARDI® Rum, 42BELOW® Vodka, BOMBAY SAPPHIRE® Gin and DEWAR’S® Blended Scotch whisky – blended with top quality ingredients. The TAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda.
Visit www.tailscocktails.com .
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005116/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
